Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...

FDA expands approval for gene therapy Elevidys

The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over. In June last year we shared that...

Sarepta announces gene therapy results

Pharmaceutical company Sarepta has announced results of Part 1 of its Phase 3 Embark gene therapy trial for Duchenne. The trial did not meet its primary endpoint: showing a difference in a change on the North Star Ambulatory Assessment (NSAA) total score – which...

FDA approves first gene therapy for Duchenne

It has been a busy time in the Duchenne arena. In the US, the FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world, and represents a very exciting step...

Gene therapy for Duchenne: latest news

Five years ago we identified gene therapy as a viable treatment for Duchenne. Today we are reflecting on the exciting and inspiring events of the past week in the gene therapy arena which are now bringing hope and cautious optimism to the Duchenne community. We have...